Sign in or create an account to add this stock to your watchlist.
About Eleven Biotherapeutics (NASDAQ:EBIO)
Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck. It is also developing systemically-administered TPTs, including VB6-845d for the treatment of multiple types of epithelial cell adhesion molecule positive solid tumors. Eleven Biotherapeutics, Inc. has a cooperative research and development agreement with the National Cancer Institute on the development of the company's targeted therapeutic, Vicinium in combination with AstraZeneca's immune checkpoint inhibitor, ImfinziTM (durvalumab), for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EBIO
CUSIPN/A
Phone617-871-9911
Debt
Debt-to-Equity RatioN/A
Current Ratio3.88
Quick Ratio3.17
Price-To-Earnings
Trailing P/E Ratio-2.96
Forward P/E Ratio-6.33
P/E GrowthN/A
Sales & Book Value
Annual Sales$430,000.00
Price / Sales365.65
Cash FlowN/A
Price / CashN/A
Book Value$0.49 per share
Price / Book6.71
Profitability
EPS (Most Recent Fiscal Year)($1.11)
Net Income$-29,020,000.00
Net MarginsN/A
Return on Equity-126.96%
Return on Assets-33.38%
Miscellaneous
Employees17
Outstanding Shares47,790,000
Eleven Biotherapeutics (NASDAQ:EBIO) Frequently Asked Questions
What is Eleven Biotherapeutics' stock symbol?
Eleven Biotherapeutics trades on the NASDAQ under the ticker symbol "EBIO."
How were Eleven Biotherapeutics' earnings last quarter?
Eleven Biotherapeutics (NASDAQ:EBIO) issued its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.03. View Eleven Biotherapeutics' Earnings History.
What price target have analysts set for EBIO?
2 equities research analysts have issued 1 year price objectives for Eleven Biotherapeutics' stock. Their forecasts range from $2.00 to $8.00. On average, they expect Eleven Biotherapeutics' share price to reach $5.00 in the next year. View Analyst Ratings for Eleven Biotherapeutics.
Are investors shorting Eleven Biotherapeutics?
Eleven Biotherapeutics saw a increase in short interest in May. As of May 15th, there was short interest totalling 6,739,239 shares, an increase of 48.5% from the April 30th total of 4,536,882 shares. Based on an average daily volume of 6,663,859 shares, the short-interest ratio is presently 1.0 days.
Who are some of Eleven Biotherapeutics' key competitors?
Some companies that are related to Eleven Biotherapeutics include Lannett (LCI), Keryx Biopharmaceuticals (KERX), ChemoCentryx (CCXI), Odonate Therapeutics (ODT), BeyondSpring (BYSI), AC Immune (ACIU), Aclaris Therapeutics (ACRS), Akebia Therapeutics (AKBA), Prothena (PRTA), Stemline Therapeutics (STML), CannTrust (CNTTF), Kura Oncology (KURA), Cara Therapeutics (CARA), Progenics Pharmaceuticals (PGNX) and Achaogen (AKAO).
Who are Eleven Biotherapeutics' key executives?
Eleven Biotherapeutics' management team includes the folowing people:
- Mr. Stephen A. Hurly, Pres, CEO & Director (Age 50)
- Dr. K. Christopher Garcia, Co-Founder and Member of Scientific Advisory Board
- Dr. Gregory L. Verdine, Co-Founder (Age 59)
- Dr. Karl Dane Wittrup Ph.D., Co-Founder and Member of Scientific Advisory Board
- Dr. Reza Dana M.D., MPH,M.Sc, Founder and Member of Scientific Advisory Board
Has Eleven Biotherapeutics been receiving favorable news coverage?
Headlines about EBIO stock have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Eleven Biotherapeutics earned a news impact score of 0.17 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 46.95 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Eleven Biotherapeutics' major shareholders?
Eleven Biotherapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include
SABBY MANAGEMENT, LLC
(7.40%),
SABBY MANAGEMENT, LLC
(7.40%), Highbridge Capital Management LLC (3.33%), Sabby Management LLC (2.57%) and Millennium Management LLC (0.51%). Company insiders that own Eleven Biotherapeutics stock include Abbie Celniker, Boxer Capital, Llc, John J Mccabe, Karen L Tubridy, Ventures Fund 2007 L Flagship and Ventures Fund Iv LP Flagship. View Institutional Ownership Trends for Eleven Biotherapeutics.
Which major investors are buying Eleven Biotherapeutics stock?
How do I buy shares of Eleven Biotherapeutics?
Shares of EBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eleven Biotherapeutics' stock price today?
One share of EBIO stock can currently be purchased for approximately $3.29.
How big of a company is Eleven Biotherapeutics?
Eleven Biotherapeutics has a market capitalization of $159.20 million and generates $430,000.00 in revenue each year. The biopharmaceutical company earns $-29,020,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. Eleven Biotherapeutics employs 17 workers across the globe.
How can I contact Eleven Biotherapeutics?
Eleven Biotherapeutics' mailing address is 215 FIRST STREET SUITE 400, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-9911 or via email at [email protected]
MarketBeat Community Rating for Eleven Biotherapeutics (EBIO)
MarketBeat's community ratings are surveys of what our community members think about Eleven Biotherapeutics and other stocks. Vote "Outperform" if you believe EBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Eleven Biotherapeutics (NASDAQ:EBIO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Eleven Biotherapeutics in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 51.98%. The high price target for EBIO is $8.00 and the low price target for EBIO is $2.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | N/A | N/A |
| Consensus Rating Score: | 3.00 | 3.00 | N/A | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $5.00 | $2.00 | N/A | N/A |
| Price Target Upside: | 51.98% upside | 33.33% upside | N/A | N/A |
Eleven Biotherapeutics (NASDAQ:EBIO) Consensus Price Target History
Eleven Biotherapeutics (NASDAQ:EBIO) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/10/2018 | Laidlaw | Initiated Coverage | Buy | $8.00 | High |  |
| 4/18/2018 | HC Wainwright | Set Price Target | Buy | $2.00 | Low | |
(Data available from 5/27/2016 forward)
Eleven Biotherapeutics (NASDAQ:EBIO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Eleven Biotherapeutics (NASDAQ EBIO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 28.70%
Institutional Ownership Percentage: 13.96%
Eleven Biotherapeutics (NASDAQ EBIO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/28/2016 | Abbie Celniker | Director | Sell | 10,031 | $3.00 | $30,093.00 | 409,915 | |
| 9/23/2016 | Ventures Fund 2007 L Flagship | Major Shareholder | Sell | 443,422 | $3.16 | $1,401,213.52 | | |
| 9/21/2016 | Ventures Fund Iv L.P Flagship | Major Shareholder | Sell | 322,723 | $3.75 | $1,210,211.25 | | |
| 9/20/2016 | Ventures Fund Iv L.P Flagship | Major Shareholder | Sell | 53,917 | $3.39 | $182,778.63 | | |
| 9/19/2016 | Ventures Fund Iv L.P Flagship | Major Shareholder | Sell | 9,700 | $3.31 | $32,107.00 | | |
| 9/15/2016 | Ventures Fund 2007 L Flagship | Major Shareholder | Sell | 46,692 | $4.18 | $195,172.56 | | |
| 9/7/2016 | Ventures Fund 2007 L Flagship | Major Shareholder | Sell | 129,497 | $4.54 | $587,916.38 | | |
| 8/15/2016 | John J Mccabe | CFO | Sell | 1,170 | $4.80 | $5,616.00 | 7,329 | |
| 6/27/2016 | Abbie Celniker | CEO | Sell | 10,029 | $2.08 | $20,860.32 | 419,946 | |
| 6/27/2016 | Karen L Tubridy | Insider | Sell | 4,372 | $2.08 | $9,093.76 | 32,753 | |
| 6/13/2016 | Boxer Capital, Llc | Major Shareholder | Sell | 1,042,000 | $2.74 | $2,855,080.00 | | |
| 2/16/2016 | John J Mccabe | SVP | Sell | 1,501 | $0.27 | $405.27 | 8,499 | |
| 12/28/2015 | Abbie Celniker | CEO | Sell | 10,155 | $2.85 | $28,941.75 | 429,975 | |
| 12/28/2015 | Eric Steven Furfine | Insider | Sell | 4,652 | $2.85 | $13,258.20 | 34,648 | |
| 5/8/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 33,400 | $13.23 | $441,882.00 | | |
| 2/2/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 17,900 | $11.62 | $207,998.00 | | |
| 1/30/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 120,000 | $11.62 | $1,394,400.00 | | |
| 1/26/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 6,300 | $11.85 | $74,655.00 | | |
| 1/22/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 6,300 | $11.82 | $74,466.00 | | |
| 1/16/2015 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 6,100 | $12.07 | $73,627.00 | | |
| 8/26/2014 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 2,000 | $11.54 | $23,080.00 | | |
| 8/20/2014 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 1,165 | $11.54 | $13,444.10 | | |
| 8/18/2014 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 2,600 | $11.81 | $30,706.00 | | |
| 8/14/2014 | Jafco Super V3 Investment Limi | Major Shareholder | Sell | 2,000 | $11.75 | $23,500.00 | | |
| 2/11/2014 | Jafco Super V3 Investment Limi | Major Shareholder | Buy | 219,790 | $10.00 | $2,197,900.00 | | |
(Data available from 1/1/2013 forward)
Eleven Biotherapeutics (NASDAQ EBIO) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Short Interest in Eleven Biotherapeutics (EBIO) Increases By 48.5%
www.americanbankingnews.com - May 26 at 1:07 AM |
 | UPDATE: Laidlaw Starts Eleven Biotherapeutics (EBIO) at Buy
www.streetinsider.com - May 22 at 9:13 AM |
 | Rounds Report: Alpine Rallies; Eleven BioTherapeutics Becomes Sesen Bio
seekingalpha.com - May 21 at 9:12 AM |
 | BRIEF-Eleven Biotherapeutics Announces Corporate Name Change To Sesen Bio
www.reuters.com - May 18 at 10:03 AM |
 | Today’s Research Reports on Stocks to Watch: Eleven Biotherapeutics and VIVUS
finance.yahoo.com - May 17 at 9:40 AM |
| Eleven Biotherapeutics (EBIO) Announces Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - May 16 at 7:12 PM |
| Eleven Biotherapeutics changes its name to Sesen Bio
seekingalpha.com - May 16 at 9:39 AM |
| Eleven Biotherapeutics beats by $0.02
seekingalpha.com - May 15 at 5:15 PM |
| Eleven Biotherapeutics Reports First Quarter Financial Results and Pipeline Updates
finance.yahoo.com - May 15 at 4:51 PM |
| Eleven Biotherapeutics (EBIO) Sees Large Increase in Short Interest
www.americanbankingnews.com - May 11 at 3:06 AM |
| Laidlaw Begins Coverage on Eleven Biotherapeutics (EBIO)
www.americanbankingnews.com - May 10 at 1:02 PM |
| Pre-Open Movers 05/07: (ATHN) (GPT) (NOG) Higher; (XRAY) (EBIO) (TSN) Lower (more...)
www.streetinsider.com - May 8 at 9:19 AM |
| Eleven Biotherapeutics (EBIO) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - May 3 at 10:54 PM |
| Zacks: Analysts Anticipate Eleven Biotherapeutics (EBIO) to Post -$0.13 Earnings Per Share
www.americanbankingnews.com - May 3 at 6:10 PM |
| Today’s Research Reports on Stocks to Watch: Midatech Pharma and Eleven Biotherapeutics
finance.yahoo.com - May 3 at 9:17 AM |
| Implied Volatility Surging for Eleven Biotherapeutics (EBIO) Stock Options
finance.yahoo.com - May 3 at 9:17 AM |
| Rounds Report: Eleven Train Is Moving Fast While Microcap Hemipherx Experienced Significant Insider Purchases
seekingalpha.com - May 2 at 9:22 AM |
| Rounds Report: Achaogen And Eleven To Clear Their Binaries For Substantial Gains
seekingalpha.com - April 28 at 4:28 PM |
| Rounds Report: Eleven Biotherapeutics Traded Further North While The Higher FDA Budget Foretells More Approvals
seekingalpha.com - April 25 at 9:30 AM |
| Rounds Report: Eleven Train Took Off While Improved FDA Policy Favors Infectious Disease Innovators
seekingalpha.com - April 24 at 9:24 AM |
| Eleven Biotherapeutics: An Assessment Of A Potential Big Winner
seekingalpha.com - April 23 at 4:28 PM |
| Today's Research Reports on Trending Tickers: Eleven Biotherapeutics and CVS Health
finance.yahoo.com - April 23 at 9:08 AM |
| Who Are The Largest Shareholders In Eleven Biotherapeutics Inc (NASDAQ:EBIO)?
finance.yahoo.com - April 22 at 9:13 AM |
| Eleven Biotherapeutics (EBIO) in Focus: Stock Moves 8.7% Higher
finance.yahoo.com - April 20 at 9:36 AM |
| Eleven Biotherapeutics (EBIO) PT Set at $2.00 by HC Wainwright
www.americanbankingnews.com - April 18 at 9:53 AM |
| Eleven Biotherapeutics (EBIO) Expected to Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - April 16 at 9:25 AM |
| Short Interest in Eleven Biotherapeutics (EBIO) Decreases By 45.3%
www.americanbankingnews.com - April 14 at 2:29 AM |
| HC Wainwright Reiterates Buy Rating for Eleven Biotherapeutics (EBIO)
www.americanbankingnews.com - April 12 at 10:45 AM |
| Eleven Biotherapeutics (EBIO) Says New Preclinical Data Highlighting its DeBouganin Program to be Presented at AACR
www.streetinsider.com - April 12 at 10:17 AM |
| 3 Things In Biotech, April 6: Bristol's Kidney Coup, Astra's Advanced Antibody, Eleven's Mysterious Presentation
seekingalpha.com - April 7 at 9:57 AM |
 | Eleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development ...
www.businesswire.com - April 4 at 5:00 PM |
| BRIEF-Eleven Biotherapeutics Reports Q4 Loss Per Share $0.22
www.reuters.com - April 4 at 5:00 PM |
| Eleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development Progress
finance.yahoo.com - April 4 at 5:00 PM |
| Eleven Bio up 22% on bullish expectations for late-stage Vicinium data
seekingalpha.com - April 3 at 4:33 PM |
| Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to Be Presented in a Plenary Session at American ...
www.businesswire.com - April 3 at 9:44 AM |
| Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to Be Presented in a Plenary Session at American Urological Association Annual Meeting
finance.yahoo.com - April 3 at 9:44 AM |
| Analysts Anticipate Eleven Biotherapeutics (EBIO) to Post -$0.17 Earnings Per Share
www.americanbankingnews.com - March 30 at 11:34 AM |
| Eleven Biotherapeutics (EBIO) Upgraded at ValuEngine
www.americanbankingnews.com - March 25 at 6:58 PM |
| Your Daily Pharma Scoop: Achaogen's Plazomicin, Eiger Provides Update On Llonafarnib, Eleven Biotherapeutics Obtains Funding
seekingalpha.com - March 24 at 4:24 PM |
| Eleven Biotherapeutics (EBIO) Prices $10M Offering of Common Stock, Warrants - StreetInsider.com
www.streetinsider.com - March 21 at 10:33 AM |
| Eleven Biotherapeutics Announces Pricing of $10.0 Million Offering Priced At-the-Market
finance.yahoo.com - March 21 at 10:33 AM |
 | Benzinga's Top Upgrades, Downgrades For March 20, 2018 - Benzinga
www.benzinga.com - March 20 at 4:23 PM |
| For Eleven Biotherapeutics, Cancer Trial Outcomes Could Be 'Major Catalyst' - Benzinga
www.benzinga.com - March 20 at 4:23 PM |
| For Eleven Biotherapeutics, Cancer Trial Outcomes Could Be 'Major Catalyst'
finance.yahoo.com - March 20 at 4:23 PM |
| Eleven Biotherapeutics (EBIO) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - March 20 at 11:56 AM |
| Eleven Biotherapeutics (EBIO) Reports Completed Enrollment in VISTA Phase 3 Registration Trial of Vicinium - StreetInsider.com
www.streetinsider.com - March 12 at 11:05 AM |
| Eleven Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 5 at 9:38 AM |
| Eleven Biotherapeutics (EBIO) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 4:24 PM |
| Eleven Biotherapeutics Inc (EBIO) Short Interest Update
www.americanbankingnews.com - February 9 at 5:01 PM |
| Eleven Biotherapeutics to Present at 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 8 at 8:53 AM |
Eleven Biotherapeutics (NASDAQ:EBIO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Eleven Biotherapeutics (NASDAQ:EBIO) Income Statement, Balance Sheet and Cash Flow Statement
Eleven Biotherapeutics (NASDAQ EBIO) Stock Chart for Sunday, May, 27, 2018
Loading chart…
